September 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on September 23, 2026 with David Sacks MB, ChB, FRCPath, Chairman, Steering Committee, National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience Inc.
Roundtable Objectives:
- As laboratories and healthcare providers strive for confidence in diabetes testing, understanding the potential impact of hemoglobin variants on HbA1c assessment remains an important consideration. Increased awareness of variant detection in HbA1c testing can provide valuable context for clinical decision-making and patient management of diabetes.
- During this virtual discussion, Dr. David Sacks will share perspectives on the evolving role of HbA1c testing, the importance of recognizing hemoglobin variants, and considerations for delivering accurate and actionable test results for diabetes management.
This roundtable discussion is sponsored by TOSOH. CAP TODAY does not endorse named products in commercial roundtables, and the publisher’s comments are his own and not necessarily reflective of CAP TODAY or College of American Pathologists policy.